Wave Life Sciences Ltd. reported financial results for quarter ended March 31, 2026.
“On April 28, 2026, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.”
Wave Life Sciences Ltd. — fact timeline
Source-grounded facts extracted from Wave Life Sciences Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Wave Life Sciences Ltd. entered into Implementation Agreement with Wave Life Sciences, Inc. (Wave-Delaware) valued at Exchange all Wave-Singapore ordinary shares for Wave-Delaware common stock on a one-for-one basis; R (effective 2026-04-15).
“In order to complete the Redomiciliation, the boards of directors of each of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation (“ Wave-Delaware ”), approved the entry by Wave-Singapore and Wave-Delaware, respectively, into an Implementation Agreement (the “ Implementation Agreement ”). The Implementation Agreement was executed by Wave-Singapore and Wave-Delaware on April 15, 2026 and provides for a statutory procedure known as a scheme of arrangement (the “ Scheme of Arrangement ”) to be implemented by Wave-Singapore and Wave-Delaware under Singapore law, subject to approval of the shareholders of Wave-Singapore and the High Court of the Republic of Singapore.”
Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.